Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
The company is facing patent challenges from generics, with the potential for a generic version of cabozantinib to launch in 2026. Exelixis is working on developing a next-generation oral TKI, zanzalintinib, to replace cabozantinib, but its success is uncertain. Investment Overview I last covered Exelixis ( NASDAQ: EXEL ) in a note for Seeking Alpha back in August 2023. The company markets and sells cabozantinib, which it describes as follows in its 2023 annual report/10K submission: Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 69 other countries: as CABOMETYX® (cabozantinib) tablets for advanced renal cell carcinoma ("RCC") (both alone and in combination with Bristol-Myers Squibb Company's ( BMY ) nivolumab (OPDIVO®)), for previously treated hepatocellular carcinoma ("HCC") and for previously treated, radioactive iodine ("RAI")-refractory diffe
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- EXEL vs. REGN: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Global Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical Developments [Yahoo! Finance]Yahoo! Finance
- Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024Business Wire
EXEL
Earnings
- 2/6/24 - Beat
EXEL
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- EXEL's page on the SEC website